Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00802425 |
Recruitment Status :
Completed
First Posted : December 4, 2008
Last Update Posted : June 26, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hearing Loss | Drug: AM-111 Drug: placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 210 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | October 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: 2
AM-111 low dose
|
Drug: AM-111
single intratympanic injection |
Placebo Comparator: 1 |
Drug: placebo
single intratympanic injection |
Experimental: 3
AM-111 high dose
|
Drug: AM-111
single intratympanic injection |
- Hearing loss [ Time Frame: 7 days ]Average change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry
- Hearing loss [ Time Frame: Days 3, 30, 90 ]Average change in hearing loss in dB between the baseline and D3, D30, and D90 for the three contiguous frequencies with the worst hearing loss, identified at study entry

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with unilateral acute sensorineural hearing loss (ASNHL) with onset 48 hours or less ago
- Mean earing loss compared with the unaffected contralateral ear of at least 30 dB in the 3 most affected contiguous frequencies
- Age ≥ 18 years and ≤ 60 years
- Negative pregnancy test for women of childbearing potential
- Able to attend the on-study visits
- Written informed consent before participation in the study
Exclusion Criteria:
- Bilateral ASNHL, if not resulting from acoustic trauma
- Suspected perilymph fistula or membrane rupture
- Barotrauma
- Average air bone gap higher than 20 dB in 3 contiguous frequencies
- History of Meniere disease, autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops, suspected retro-cochlear lesion or fluctuating hearing loss
- Previous ASNHL incident within the past 6 weeks
- Evidence of acute or chronic otitis media or otitis externa on examination
- Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks
- Any ongoing or planned concomitant medication for the treatment of tinnitus until 30 days after administration
- Any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics, quinine etc.) in the past 6 months prior to study inclusion
- History of drug abuse or alcoholism
- Any clinically relevant respiratory, cardiovascular, neurological (except vertigo or tinnitus), or psychiatric disorders
- Known hypersensitivity, allergy or intolerance to the study medication or any history of severe abnormal drug reaction
- Women who are breast-feeding, pregnant or who plan a pregnancy during the trial
- Women of childbearing potential who declare being unwilling or unable to practice contraception such as combined oral contraceptives, injectables, hormonal intra-uterine devices, vasectomised partner or sexual abstinence
- Concurrent participation in another clinical trial or participation in another clinical trial within 30 days prior to study entry
- Any current anticoagulant therapy (e.g. Aspirin, Marcumar, etc)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00802425
Germany | |
LMU Munich Klinikum Grosshadern | |
Munich, Germany, 81366 |
Study Director: | Markus M Suckfüll, MD | LMU Munich |
Responsible Party: | Auris Medical AG |
ClinicalTrials.gov Identifier: | NCT00802425 |
Other Study ID Numbers: |
AM-111-CL-08-01 EudraCT number 2008-000132-40 |
First Posted: | December 4, 2008 Key Record Dates |
Last Update Posted: | June 26, 2014 |
Last Verified: | June 2014 |
Sudden hearing loss Sudden deafness Acoustic trauma Noise trauma |
Hearing Loss Deafness Hearing Loss, Sensorineural Hearing Disorders Ear Diseases |
Otorhinolaryngologic Diseases Sensation Disorders Neurologic Manifestations Nervous System Diseases |